Efficient treatment of Parkinson’s disease using ultrasonography-guided rhFGF20 proteoliposomes

References

• Aryal M, Arvanitis CD, Alexander PM, et al. (2014). Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev 72:94–109.
   PubMed Web of Science ®Google Scholar
• Aryal M, Vykhodtseva N, Zhang Y-Z, et al. (2015). Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J Control Release 204:60–9.
   PubMed Web of Science ®Google Scholar
• Basu A, Li X, Leong SS. (2011). Refolding of proteins from inclusion bodies: rational design and recipes. Appl Microbiol Biotechnol 92:241–51.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. (2009). The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235–53.
   PubMed Web of Science ®Google Scholar
• Correia AS. (2007). Fibroblast growth factor-20 increases the yield of midbrain dopaminergic neurons derived from human embryonic stem cells. Front Neuroanat 1:4.
   PubMed Web of Science ®Google Scholar
• Grothe C, Timmer M, Scholz T, et al. (2004). Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. Neurobiol Dis 17:163–70.
   PubMed Web of Science ®Google Scholar
• Hartmann A, Hunot S, Michel PP, et al. (2000). Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci USA 97:2875–80.
   PubMed Web of Science ®Google Scholar
• Itoh N, Ohta H. (2013). Roles of FGF20 in dopaminergic neurons and Parkinson’s disease. Front Mol Neurosci 6:15.
   PubMed Web of Science ®Google Scholar
• Jia X, Tian H, Tang L, et al. (2015). High-efficiency expression of TAT-bFGF fusion protein in Escherichia coli and the effect on hypertrophic scar tissue. PLoS One 10:e0117448.
   PubMed Web of Science ®Google Scholar
• Kobus T, Zervantonakis IK, Zhang Y, et al. (2016). Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. J Control Release 238:281–8.
   PubMed Web of Science ®Google Scholar
• Konofagou EE. (2012). Optimization of the ultrasound-induced blood-brain barrier opening. Theranostics 2:1223–37.
   PubMed Web of Science ®Google Scholar
• Liu X, Chen Y, Wu X, et al. (2012). SUMO fusion system facilitates soluble expression and high production of bioactive human fibroblast growth factor 23 (FGF23). Appl Microbiol Biotechnol 96:103–11.
   PubMed Web of Science ®Google Scholar
• Middelberg AP. (2002). Preparative protein refolding. Trends Biotechnol 20:437–43.
   PubMed Web of Science ®Google Scholar
• O’Reilly MA, Waspe AC, Ganguly M, et al. (2011). Focused-ultrasound disruption of the blood-brain barrier using closely-timed short pulses: influence of sonication parameters and injection rate. Ultrasound Med Biol 37:587–94.
   PubMed Web of Science ®Google Scholar
• Ohmachi S, Mikami T, Konishi M, et al. (2003). Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J Neurosci Res 72:436–43.
   PubMed Web of Science ®Google Scholar
• Ohmachi S, Watanabe Y, Mikami T, et al. (2000). FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun 277:355–60.
   PubMed Web of Science ®Google Scholar
• Pan J, Li H, Wang Y, et al. (2012). Fibroblast growth factor 20 (FGF20) polymorphism is a risk factor for Parkinson’s disease in Chinese population. Parkinsonism Relat Disord 18:629–31.
   PubMed Web of Science ®Google Scholar
• Park E-J, Zhang Y-Z, Vykhodtseva N, et al. (2012). Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release 163:277–84.
   PubMed Web of Science ®Google Scholar
• Patel MM, Patel BM. (2017). Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs 31:109–33.
   PubMed Web of Science ®Google Scholar
• Schober A. (2004). Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–24.
   PubMed Web of Science ®Google Scholar
• Shimada H, Yoshimura N, Tsuji A, et al. (2009). Differentiation of dopaminergic neurons from human embryonic stem cells: modulation of differentiation by FGF-20. J Biosci Bioeng 107:447–54.
   PubMed Web of Science ®Google Scholar
• Sleeman IJ, Boshoff EL, Duty S. (2012). Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Neuropharmacology 63:1268–77.
   PubMed Web of Science ®Google Scholar
• Sun XW, Wang XH, Yao YB. (2014). Co-expression of Dsb proteins enables soluble expression of a single-chain variable fragment (scFv) against human type 1 insulin-like growth factor receptor (IGF-1R) in E. coli. World J Microbiol Biotechnol 30:3221–7.
   PubMed Web of Science ®Google Scholar
• Tatton WG, Chalmers-Redman R, Brown D, et al. (2003). Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53(Suppl. 3):S61–S70,discussion S70–2.
   PubMed Web of Science ®Google Scholar
• Thisse B, Thisse C. (2005). Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 287:390–402.
   PubMed Web of Science ®Google Scholar
• Thuret S, Bhatt L, O'Leary DDM, et al. (2004). Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta. Mol Cell Neurosci 25:394–405.
   PubMed Web of Science ®Google Scholar
• Tian X-Q, Ni X-W, Xu H-L, et al. (2017). Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. Int J Nanomed 12:7103–19.
   PubMed Web of Science ®Google Scholar
• Tian H, Zhao Y, Chen N, et al. (2016). High production in E. coli of biologically active recombinant human fibroblast growth factor 20 and its neuroprotective effects. Appl Microbiol Biotechnol 100:3023–34.
   PubMed Web of Science ®Google Scholar
• Tolleson CM, Fang JY. (2013). Advances in the mechanisms of Parkinson's disease. Discov Med 15:61–6.
   PubMed Web of Science ®Google Scholar
• Vlachos F, Tung YS, Konofagou EE. (2010). Permeability assessment of the focused ultrasound-induced blood-brain barrier opening using dynamic contrast-enhanced MRI. Phys Med Biol 55:5451–66.
   PubMed Web of Science ®Google Scholar
• Walkinshaw G, Waters CM. (1994). Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 63:975–87.
   PubMed Web of Science ®Google Scholar
• Wang H, Xiao Y, Fu L, et al. (2010). High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol 10:14.
   PubMed Web of Science ®Google Scholar
• Zhu G, Chen G, Shi L, et al. (2015). PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson’s disease. Mol Neurobiol 51:32–42.
   PubMed Web of Science ®Google Scholar